Skip to content

Biological Markers for the Diagnosis of Central Nervous System Infective Diseases

Diagnosis Value of Procalcitonin, Interleukin-6, AgiotensininⅡin the Cerebrospinal Fluid of Patients With Central Nervous System Infective Diseases

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02278016
Enrollment
150
Registered
2014-10-29
Start date
2014-08-31
Completion date
2017-07-31
Last updated
2016-01-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection

Keywords

procalcitonin, interleukin-6, agiotensininⅡ

Brief summary

Bacterial meningitis is a potentially life-threatening disease that is associated with substantial neurological morbidity and mortality. Accurate diagnosis is essential to improve outcome and prevent antibiotic overuse. Here we try to explore new biological markers for the diagnosis of the central nervous system infection disease.

Detailed description

To investigate the diagnosis value of procalcitonin,interleukin-6, agiotensininⅡin the cerebrospinal fluid in the central nervous system infection disease.

Interventions

None listed

Sponsors

Xijing Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
13 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Aged 13 years or older; 2. At least two of the following clinical characteristics:headache, fever, neck stiffness, mental symptoms or consciousness impairment or seizures 3. Patients' family signed informed consent.

Exclusion criteria

1. Contraindications to lumbar puncture 2. Patients with active malignancy

Design outcomes

Primary

MeasureTime frameDescription
Levels of procalcitonin, interleukin-6, agiotensininⅡ in the serum and cerebrospinal fluid36 monthsmeet the clinical diagnostic criteria for the central nervous system infection disease, the blood and cerebrospinal fluid samples after onset.

Countries

China

Contacts

Primary Contactjiang wen, MD
jiangwen@fmmu.edu.cn029-84771319

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026